One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Starting chronic hemodialysis twice weekly: when less is more
Mariana Murea, Kamyar Kalantar-Zadeh
doi : 10.1093/ndt/gfac261
Nephrology Dialysis Transplantation, Volume 37, Issue 12, December 2022, Pages 2297–2299
The chronology of the clinical cardiorenal links and health outcomes: problematic issues of the cardiorenal syndrome construct
Carmine Zoccali, Francesca Mallamaci
doi : 10.1093/ndt/gfac180
Nephrology Dialysis Transplantation, Volume 37, Issue 12, December 2022, Pages 2300–2302
Is there a place for faecal microbiota transplantation in chronic kidney disease?
Nicolas Benech, Laetitia Koppe
doi : 10.1093/ndt/gfac277
Nephrology Dialysis Transplantation, Volume 37, Issue 12, December 2022, Pages 2303–2306
Smoothing transition to dialysis to improve early outcomes after dialysis initiation among old and frail adults—a narrative review
Elke Schaeffner
doi : 10.1093/ndt/gfab342
Nephrology Dialysis Transplantation, Volume 37, Issue 12, December 2022, Pages 2307–2313
The number of patients ≥65 years of age suffering from advanced chronic kidney disease and transitioning to end-stage kidney disease (ESKD) is increasing. However, elderly patients often have poor outcomes once haemodialysis is initiated, including high mortality within the first year as well as fast cognitive and functional decline and diminished quality of life.
The emerging role of the apelinergic system in kidney physiology and disease
Peter Janssens, Jean-Paul Decuypere, Bert Bammens, Catherine Llorens-Cortes, Rudi Vennekens, Djalila Mekahli
doi : 10.1093/ndt/gfab070
Nephrology Dialysis Transplantation, Volume 37, Issue 12, December 2022, Pages 2314–2326
The apelinergic system (AS) is a novel pleiotropic system with an essential role in renal and cardiovascular physiology and disease, including water homeostasis and blood pressure regulation. It consists of two highly conserved peptide ligands, apelin and apela, and a G-protein-coupled apelin receptor. The two ligands have many isoforms and a short half-life and exert both similar and divergent effects.
Sofosbuvir-based hepatitis C therapies in patients with chronic and end-stage kidney disease
Meghan E Sise, Thomas McQuaid, Paul Martin
doi : 10.1093/ndt/gfab072
Nephrology Dialysis Transplantation, Volume 37, Issue 12, December 2022, Pages 2327–2334
Sofosbuvir (SOF), a nucleotide inhibitor of the hepatitis C virus (HCV) polymerase, is a component of several all-oral HCV therapies. GS-331007, SOF’s predominant metabolite, is renally eliminated and accumulates 5- to 20-fold in patients with advanced chronic kidney disease (CKD) or undergoing hemodialysis (HD), respectively. Preclinical data did not determine whether these exposures represented a risk for toxicity.
Cardiopulmonary exercise testing in patients with end-stage kidney disease: principles, methodology and clinical applications of the optimal tool for exercise tolerance evaluation
Eva Pella, Afroditi Boutou, Aristi Boulmpou, Christodoulos E Papadopoulos, Aikaterini Papagianni, Pantelis Sarafidis
doi : 10.1093/ndt/gfab150
Nephrology Dialysis Transplantation, Volume 37, Issue 12, December 2022, Pages 2335–2350
Chronic kidney disease (CKD), especially end-stage kidney disease (ESKD), is associated with an increased risk for cardiovascular events and all-cause mortality. Exercise intolerance as well as reduced cardiovascular reserve is extremely common in patients with CKD. Cardiopulmonary exercise testing (CPET) is a non-invasive, dynamic technique that provides an integrative evaluation of cardiovascular, pulmonary, neuropsychological and metabolic function during maximal or submaximal exercise, allowing the evaluation of functional reserves of these systems.
Definition, diagnosis and clinical management of non-obstructive kidney dysplasia: a consensus statement by the ERKNet Working Group on Kidney Malformations
Stefan Kohl, Fred E Avni, Peter Boor, Valentina Capone, William L Clapp, Diego De Palma, Tess Harris, Laurence Heidet, Alina C Hilger, Helen Liapis, Marc Lilien, Gianantonio Manzoni, Giovanni Montini, Susanna Negrisolo, Marie-Jeanne Pierrat, Ann Raes, Heiko Reutter, Michiel F Schreuder, Stefanie Weber, Paul J D Winyard, Adrian S Woolf, Franz Schaefer, Max C Liebau
doi : 10.1093/ndt/gfac207
Nephrology Dialysis Transplantation, Volume 37, Issue 12, December 2022, Pages 2351–2362
Kidney dysplasia is one of the most frequent causes of chronic kidney failure in children. While dysplasia is a histological diagnosis, the term ‘kidney dysplasia’ is frequently used in daily clinical life without histopathological confirmation. Clinical parameters of kidney dysplasia have not been clearly defined, leading to imprecise communication amongst healthcare professionals and patients. This lack of consensus hampers precise disease understanding and the development of specific therapies.
Mass spectrometry imaging and its place in nephrology
Michael Groessl, Bruno Vogt
doi : 10.1093/ndt/gfab359
Nephrology Dialysis Transplantation, Volume 37, Issue 12, December 2022, Pages 2363–2365
Bombesin receptor-activated protein exacerbates cisplatin-induced AKI by regulating the degradation of SIRT2
Liang Peng, Di Liu, Haiyang Liu, Ming Xia, Lili Wan, Mei Li, Junyong Zhao, Chengyuan Tang, Guochun Chen, Xiangpin Qu, Zheng Dong, Hong Liu
doi : 10.1093/ndt/gfac164
Nephrology Dialysis Transplantation, Volume 37, Issue 12, December 2022, Pages 2366–2385
Acute kidney injury (AKI) is a public health problem with no specific therapies in the clinic and the underlying pathogenesis of AKI remains obscure. Bombesin receptor-activated protein (BRAP, C6ORF89 protein) was initially discovered as a ligand for a previously orphan G-protein-coupled receptor bombesin-like receptor-3. At present, accepted biological effects of BRAP include cell cycle progression, wound repair and the activation of histone deacetylases.
Long-term impact of cardiorenal syndromes on major outcomes based on their chronology: a comprehensive French nationwide cohort study
Jean-Michel Halimi, Jean-Baptiste de Fréminville, Philippe Gatault, Arnaud Bisson, Juliette Gueguen, Nicolas Goin, Bénédicte Sautenet, Valentin Maisons, Julien Herbert, Denis Angoulvant, Laurent Fauchier
doi : 10.1093/ndt/gfac153
Nephrology Dialysis Transplantation, Volume 37, Issue 12, December 2022, Pages 2386–2397
Cardiorenal syndromes (CRSs) are reputed to result in worse prognosis than isolated heart failure (HF) and chronic kidney disease (CKD). Whether it is true for all major outcomes over the long-term regardless of CRS chronology (simultaneous, cardiorenal and renocardiac CRS) is unknown.
Heterozygous COL4A3/COL4A4 mutations: the hidden part of the iceberg?
Antonio Mastrangelo, Catarina Madeira, Pierangela Castorina, Marisa Giani, Giovanni Montini
doi : 10.1093/ndt/gfab334
Nephrology Dialysis Transplantation, Volume 37, Issue 12, December 2022, Pages 2398–2407
Single mutations in COL4A3/COL4A4 genes have been described in patients with autosomal dominant Alport syndrome and thin basement membrane nephropathy, without a shared definition of these patients within the medical community. We aimed to better categorize this clinical entity by examining clinical manifestations, family history, pathological features and genetics.
Opioid prescribing practices in chronic kidney disease: a population-based cohort study
Amber O Molnar, Sarah E Bota, Kyla Naylor, Danielle M Nash, Graham Smith, Rita S Suri, Manish M Sood, Tara Gomes, Amit X Garg
doi : 10.1093/ndt/gfab343
Nephrology Dialysis Transplantation, Volume 37, Issue 12, December 2022, Pages 2408–2417
Chronic pain is common, and its management is complex in patients with chronic kidney disease (CKD), but limited data are available on opioid prescribing. We examined opioid prescribing for non-cancer and non-end-of-life care in patients with CKD.
Renal events in patients receiving neprilysin inhibitors: a systematic review and meta-analysis
Clara Vollmer Barbosa, Hannah Lang, Anette Melk, Bernhard M W Schmidt
doi : 10.1093/ndt/gfac001
Nephrology Dialysis Transplantation, Volume 37, Issue 12, December 2022, Pages 2418–2428
While it is well known that angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARBs) increase the risk of acute renal failure, the role of neprilysin inhibition (NEPi) is unclear and some physicians are reluctant to prescribe sacubitril/valsartan because of safety concerns. This meta-analysis aimed to examine the risk for renal events, progression of chronic kidney disease (CKD) or progression to dialysis on combined NEPi and ACEi/ARBs compared with ACEi or ARBs.
Rapidly progressive IgA nephropathy: clinicopathological characteristics and outcomes assessed according to the revised definition of the KDIGO 2021 Guideline
Bingxin Yu, Sufang Shi, Jicheng Lv, Lijun Liu, Xujie Zhou, Li Zhu, Pei Chen, Hongyu Yang, Zi Wang, Suxia Wang, Jonathan Barratt, Hong Zhang
doi : 10.1093/ndt/gfac004
Nephrology Dialysis Transplantation, Volume 37, Issue 12, December 2022, Pages 2429–2437
Rapidly progressive immunoglobulin A nephropathy (RPIgAN) is a severe clinical phenotype of IgAN associated with a poor outcome. The recently published Kidney Disease: Improving Global Outcomes (KDIGO) 2021 Guideline for the Management of Glomerular Diseases has proposed a new definition for RPIgAN that is based simply on a ≥50% decline in the estimated glomerular filtration rate (eGFR) over ≤3 months.
Barriers to conservative care from patients’ and nephrologists’ perspectives: the CKD-REIN study
Aghilès Hamroun, Elodie Speyer, Carole Ayav, Christian Combe, Denis Fouque, Christian Jacquelinet, Maurice Laville, Sophie Liabeuf, Ziad A Massy, Roberto Pecoits-Filho, Bruce M Robinson, François Glowacki, Bénédicte Stengel, Luc Frimat, CKD-REIN study Collaborators
doi : 10.1093/ndt/gfac009
Nephrology Dialysis Transplantation, Volume 37, Issue 12, December 2022, Pages 2438–2448
Conservative care is increasingly considered an alternative to kidney replacement therapy for kidney failure management, mostly among the elderly. We investigated its status and the barriers to its implementation from patients’ and providers’ perspectives.
Patient preferences for cancer screening in chronic kidney disease: a best–worst scaling survey
Laura J James, Germaine Wong, Allison Tong, Jonathan C Craig, Kirsten Howard, Martin Howell
doi : 10.1093/ndt/gfab360
Nephrology Dialysis Transplantation, Volume 37, Issue 12, December 2022, Pages 2449–2456
Despite an increased cancer risk for patients with chronic kidney disease (CKD), uptake of cancer screening varies due to competing priorities and complex health-related issues. This study aimed to elicit the preferences and important attributes of cancer screening in patients with CKD.
Kidney injury rates after unilateral nephrectomy in childhood—a systematic review and meta-analysis
Sander Groen in ‘t Woud, Alessandro Gobino, Nel Roeleveld, Lambert P W J van den Heuvel, Wout F J Feitz, Loes F M van der Zanden, Michiel F Schreuder
doi : 10.1093/ndt/gfac021
Nephrology Dialysis Transplantation, Volume 37, Issue 12, December 2022, Pages 2457–2473
Unilateral nephrectomy is a relatively common procedure in children which results in a solitary functioning kidney (SFK). Living with an SFK predisposes to kidney injury, but it remains unknown which children are most at risk. We aimed to investigate kidney injury rates in patients who underwent unilateral nephrectomy in childhood and to investigate differences among nephrectomies performed for a congenital anomaly, malignancy or other condition.
Parathyroid hormone and phosphate homeostasis in patients with Bartter and Gitelman syndrome: an international cross-sectional study
Maartje F A Verploegen, Rosa Vargas-Poussou, Stephen B Walsh, Harika Alpay, Atefeh Amouzegar, Gema Ariceta, Bahriye Atmis, Justine Bacchetta, Peter Bárány, Stéphanie Baron, Umut Selda Bayrakci, Hendrica Belge, Martine Besouw, Anne Blanchard, Arend B?kenkamp, Olivia Boyer, Kathrin Burgmaier, Lorenzo A Cal?, Stéphane Decramer, Olivier Devuyst, Maria van Dyck, Pietro Manuel Ferraro, Marc Fila, Telma Francisco, Gian Marco Ghiggeri, Leire Gondra, Stefano Guarino, Nakysa Hooman, Ewout J Hoorn, Pascal Houillier, Konstantinos Kamperis, Jameela A Kari, Martin Konrad, Elena Levtchenko, Laura Lucchetti, Francesca Lugani, Pierluigi Marzuillo, Barian Mohidin, Thomas J Neuhaus, Abdaldafae Osman, Svetlana Papizh, Manel Perell?, Maarten B Rookmaaker, Valerie Said Conti, Fernando Santos, Ghalia Sawaf, Erkin Serdaroglu, Maria Szczepanska, Francesca Taroni, Rezan Topaloglu, Francesco Trepiccione, Enrico Vidal, Elizabeth R Wan, Lutz Weber, Zeynep Yuruk Yildirim, Selçuk Yüksel, Galia Zlatanova, Detlef Bockenhauer, Francesco Emma, Tom Nijenhuis
doi : 10.1093/ndt/gfac029
Nephrology Dialysis Transplantation, Volume 37, Issue 12, December 2022, Pages 2474–2486
Small cohort studies have reported high parathyroid hormone (PTH) levels in patients with Bartter syndrome and lower serum phosphate levels have anecdotally been reported in patients with Gitelman syndrome. In this cross-sectional study, we assessed PTH and phosphate homeostasis in a large cohort of patients with salt-losing tubulopathies.
Dissecting the genotype-phenotype correlation of COL4A5 gene mutation and its response to renin-angiotensin-aldosterone system blockers in Chinese male patients with Alport syndrome
Hongling Di, Jiahui Zhang, Erzhi Gao, Chunxia Zheng, Xianghua Huang, Qing Wang, Xiaomin Yu, Zhihong Liu
doi : 10.1093/ndt/gfac002
Nephrology Dialysis Transplantation, Volume 37, Issue 12, December 2022, Pages 2487–2495
Alport syndrome (AS) is an inherited type IV collagen–related disorder with an irreversible tendency to progress to end-stage renal disease (ESRD). X-linked AS (XLAS) is caused by mutations in the COL4A5 gene. The aim of this study was to investigate the effects of underlying mutations on clinical manifestations and the response to therapy in XLAS.
Lifelong effect of therapy in young patients with the COL4A5 Alport missense variant p.(Gly624Asp): a prospective cohort study
Jan Boeckhaus, Julia Hoefele, Korbinian M Riedhammer, Mato Nagel, Bodo B Beck, Mira Choi, Maik Gollasch, Carsten Bergmann, Joseph E Sonntag, Victoria Troesch, Johanna Stock, Oliver Gross
doi : 10.1093/ndt/gfac006
Nephrology Dialysis Transplantation, Volume 37, Issue 12, December 2022, Pages 2496–2504
Angiotensin-converting enzyme inhibitors (ACEis) have evolved as a first-line therapy for delaying end-stage renal failure (ESRF) in Alport syndrome (AS). The present study tested the hypothesis of a superior nephroprotective potential of an early ACEi intervention, examining a cohort with the COL4A5 missense variant p.(Gly624Asp).
Hypophosphatemia in critically ill patients undergoing Sustained Low-Efficiency Dialysis with standard dialysis solutions
Francesca Di Mario, Giuseppe Regolisti, Umberto Maggiore, Maria Chiara Pacchiarini, Brenda Menegazzo, Paolo Greco, Caterina Maccari, Cristina Zambrano, Chiara Cantarelli, Valentina Pistolesi, Santo Morabito, Enrico Fiaccadori
doi : 10.1093/ndt/gfac159
Nephrology Dialysis Transplantation, Volume 37, Issue 12, December 2022, Pages 2505–2513
In patients admitted to the Intensive Care Unit (ICU), Kidney Replacement Therapy (KRT) is an important risk factor for hypophosphataemia. However, studies addressing the development of hypophosphatemia during prolonged intermittent KRT modalities are lacking. Thus, we evaluated the incidence of hypophosphatemia during Sustained Low-Efficiency Dialysis (SLED) in ICU patients; we also examined the determinants of post-SLED serum phosphate level (s-P) and the relation between s-P and phosphate supplementation and ICU mortality.
Outcomes of incident patients treated with incremental haemodialysis as compared with standard haemodialysis and peritoneal dialysis
David A Jaques, Belen Ponte, Fadi Haidar, Anne Dufey, Sebastian Carballo, Sophie De Seigneux, Patrick Saudan
doi : 10.1093/ndt/gfac205
Nephrology Dialysis Transplantation, Volume 37, Issue 12, December 2022, Pages 2514–2521
Residual kidney function is considered better preserved with incremental haemodialysis (I-HD) or peritoneal dialysis (PD) as compared with conventional thrice-weekly HD (TW-HD) and is associated with improved survival. We aimed to describe outcomes of patients initiating dialysis with I-HD, TW-HD or PD.
Comparison of measured vs kinetic-model predicted phosphate removal during hemodialysis and hemodiafiltration
John T Daugirdas
doi : 10.1093/ndt/gfac223
Nephrology Dialysis Transplantation, Volume 37, Issue 12, December 2022, Pages 2522–2527
To what extent hemodiafiltration (HDF) improves management of hyperphosphatemia over hemodialysis (HD) is a subject of ongoing investigation.
Neutrophil:lymphocyte ratio correlates with the uremic toxin indoxyl sulfate and predicts the risk of death in patients on hemodialysis
Guillaume Lano, Marion Sallée, Marion Pelletier, Stanislas Bataille, Megan Fraisse, Nathalie McKay, Philippe Brunet, Laetitia Dou, Stéphane Burtey
doi : 10.1093/ndt/gfab350
Nephrology Dialysis Transplantation, Volume 37, Issue 12, December 2022, Pages 2528–2537
Chronic kidney disease (CKD) is a major public health issue associated with increased cardiovascular, infectious and all-cause mortality. The neutrophil:lymphocyte ratio (NLR) is a predictive marker of the risk of death and cardiovascular events. Uremic toxins, notably indoxyl sulfate (IS), are involved in immune deficiency and cardiovascular complications associated with CKD. The aim of this study was to assess whether the NLR was related to uremic toxins and could predict clinical outcome in hemodialysis (HD) patients.
Measuring quality of life in trials including patients on haemodialysis: methodological issues surrounding the use of the Kidney Disease Quality of Life Questionnaire
Hannah M Worboys, Nicola J Cooper, James O Burton, Hannah M L Young, Ghazala Waheed, James Fotheringham, Laura J Gray
doi : 10.1093/ndt/gfac170
Nephrology Dialysis Transplantation, Volume 37, Issue 12, December 2022, Pages 2538–2554
Haemodialysis (HD) treatment causes a significant decrease in quality of life (QoL). When enrolled in a clinical trial, some patients are lost prior to follow-up because they die or they receive a kidney transplant. It is unclear how these patients are dealt with in the analysis of QoL data. There are questions surrounding the consistency of how QoL measures are used, reported and analysed.
Evolution of humoral lesions on follow-up biopsy stratifies the risk for renal graft loss after antibody-mediated rejection treatment
Antonin Bouchet, Brieuc Muller, Jerome Olagne, Thomas Barba, Mélanie Joly, Augustin Obrecht, Maud Rabeyrin, Frédérique Dijoud, Cécile Picard, Sarah Mezaache, Antoine Sicard, Alice Koenig, Anne Parissiadis, Valérie Dubois, Emmanuel Morelon, Sophie Caillard, Olivier Thaunat
doi : 10.1093/ndt/gfac192
Nephrology Dialysis Transplantation, Volume 37, Issue 12, December 2022, Pages 2555–2568
The standard-of-care protocol, based on plasma exchanges, high-dose intravenous immunoglobulin and optimization of maintenance immunosuppression, can slow down the evolution of antibody-mediated rejection (AMR), but with high interindividual variability. Identification of a reliable predictive tool of the response to AMR treatment is a mandatory step for personalization of the follow-up strategy and to guide second-line therapies.
Outcomes of kidney transplantation in patients with myeloma and amyloidosis in the USA
Jia H Ng, Stephanie Izard, Naoka Murakami, Kenar D Jhaveri, Amy Sharma, Vinay Nair
doi : 10.1093/ndt/gfac196
Nephrology Dialysis Transplantation, Volume 37, Issue 12, December 2022, Pages 2569–2580
Recent improvement in treatment and patient survival has opened the eligibility of kidney transplantation to patients who developed end-stage kidney disease (ESKD) from plasma cell dyscrasias (PCDs). Data on clinical outcomes in this population are lacking.
RtNet: a deep hybrid neural network for the identification of acute rejection and chronic allograft nephropathy after renal transplantation using multiparametric MRI
Rui Zhi, Xiao-Dong Zhang, Ying Hou, Ke-Wen Jiang, Qiao Li, Jing Zhang, Yu-Dong Zhang
doi : 10.1093/ndt/gfac005
Nephrology Dialysis Transplantation, Volume 37, Issue 12, December 2022, Pages 2581–2590
Reliable diagnosis of the cause of renal allograft dysfunction is of clinical importance. The aim of this study is to develop a hybrid deep-learning approach for determining acute rejection (AR), chronic allograft nephropathy (CAN) and renal function in kidney-allografted patients by multimodality integration.
Generalizability of DAPA-CKD trial to the real-world setting of outpatient CKD clinics in Italy
Roberto Minutolo, Maria Elena Liberti, Michele Provenzano, Carlo Garofalo, Silvio Borrelli, Carmela Iodice, Luca De Nicola
doi : 10.1093/ndt/gfac276
Nephrology Dialysis Transplantation, Volume 37, Issue 12, December 2022, Pages 2591–2593
